In March, the Basque company iLine Microsystems plans to launch the microINR system, a new product for determining INR (International Normalized Ratio) to monitor patients undergoing Oral Anticoagulant Therapy (OAT), such as Sintrom®.

It is considered that at least 1.5% of the population in industrialised countries is under OAT and the medical community admits that, in patients undergoing this therapy, self-control provides effective monitoring and an improvement in patients' quality of life. On the other hand, health care professionals are increasingly burdened by routine OAT monitoring, mainly due to the increase in the number of patients and the reductions in the number of health centres and their resources.

For these reasons, self-monitoring rates for self-control grow every year, but the widespread use of self-control requires more profitable systems that are easier to use, painless and reliable than the current ones.

iLine Microsystems has developed microINR to respond to the needs that the current models don't cover, which can be used by health care professionals in decentralised centres and patients - as a self-control method.

microINR has a compact and easy-to-use design. It complies with the requirement of needing a small sample size and provides quality control at several levels. microINR uses patented technology to provide accurate and reproducible results.

iLine Microsystems has just completed the installation of the production line at the San Sebastián Technology Park. The microINR system has already received its CE marking for hospital use, while CE marking for self-control use is expected in February, and iLine Microsystems is preparing its global launch in March.